TIBSOVO’s Potential: Susan Pandya, MD, on FDA Priority Review for IDH1-Mutated MDS Acute Myelogenous Leukemia 1 Min Read8 In the interview, Susan Pandya, MD, Vice President of Clinical Development at Servier Pharmaceuticals, discusses the pivotal FDA acceptance and…
Amir T. Fathi MD [slides]- IDH 1/2-Mutant AML Treatment Acute Myelogenous Leukemia 1 Min Read17 Amir T. Fathi MD Associate Professor of Medicine, Harvard Medical School Program Director, Center for Leukemia- Massachusetts General Hospital Join…
